Key Drivers
- Margin expansion
- Debt burden
- Cash volatility
AIAI Summary
ELAN has shifted from a distressed turnaround to a legitimate self-help compounder, but the stock still looks like a prove-it story because margin gains and new products must translate into sustained free cash flow and lower leverage before the current valuation can rerate.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin expansion
- •Debt burden
- •Cash volatility
ELAN's quarterly margins and liquidity improved, but weak profitability, leveraged balance sheet, and inconsistent cash flow keep the investment case cautious despite strong gross margins.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance test
- •Support holding
ELAN has turned constructive over the last month with higher lows and a close at $25.00, but it is testing resistance near $24.7-$25.0 and needs to hold $24.0 to keep the bullish case intact.
Sharp pullback from $24.74 to $24.09 on 2026-07-01 shows selling on rallies
Sentiment & News
Key News Insights:
- •Vaccine approval
- •Venture funding
- •Options interest
Elanco is strengthening its animal-health pipeline with USDA approval for TruCan Ultra Lyme-L4 and a $25 million venture platform, while rising options activity is keeping ELAN in focus.
This news is mildly positive for ELAN as it supports growth prospects and signals increased investor attention
Similar Companies in Healthcare
Other companies in the same sector with AI ratings